How to approach genome wars in sepsis?

Critical Care

Volumn 15, Issue 6, 2011, Pages

  Hawiger, Jack ^a   Musser, James M ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD VESSEL PERMEABILITY; COGNITIVE DEFECT; DEATH; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIAL DYSFUNCTION; EXOME; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL DISEASE; GENE SEQUENCE; GENOMICS; HOSPITALIZATION; HOST PATHOGEN INTERACTION; HUMAN; HYPOTENSION; INFECTION; INNATE IMMUNITY; MICROCIRCULATION; MORTALITY; MULTIPLE ORGAN FAILURE; NATIONAL HEALTH ORGANIZATION; NEUTROPHIL; NOTE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; THERAPY DELAY; THROMBOCYTE FUNCTION; EDITORIAL; GENETICS; UNITED STATES;

GENOMICS; HUMANS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); SEPSIS; UNITED STATES;

EID: 82555192788     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10482     Document Type: Note

References (13)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Hospitalization Rates for Patients Aged >65 Years with Septicemia or Sepsis by Age Group - National Hospital Discharge Survey, United States, 2000-2007. , http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a6.htm
3. Mitka M. Hospitalizations for extreme conditions mean extreme expenses, study verifies. JAMA 2010, 304:2579-2580. 10.1001/jama.2010.1803, 21156942.
4. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010, 304:1787-1794. 10.1001/jama.2010.1553, 20978258.
5. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, , et al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437, International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases.
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, . Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
7. National Heart Lung and Blood Institute: Blood Systems Response to Sepsis. , http://www.nhlbi.nih.gov/meetings/workshops/bsrts.htm
8. Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011, 23:273-277. 10.1097/BOR.0b013e3283456797, 21427577.
9. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures and future hopes. Infect Dis Clin North Am 1999, 13:285-297. 10.1016/S0891-5520(05)70075-1, 10340167.
10. Goldenberg NM, Steinberg BE, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011, 3:88ps25. 10.1126/scitranslmed.3002011, 21697528.
11. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999, 340:1555-1564. 10.1056/NEJM199905203402007, 10332019.
12. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
13. Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care 2008, 23:455-460. 10.1016/j.jcrc.2007.08.003, 19056006.